Entera Bio advances EB613 toward Phase 3 osteoporosis trial, targets late 2026 site activationNov 6Quarterly updateEntera Bio Ltd.
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Entera Bio reports Q2 2026 results, cites FDA alignment on EB613 Phase 3 designAug 7Quarterly updateEntera Bio Ltd.
Lilly wins two label supplements: orforglipron tablet and teriparatide solutionAug 4Weekly roundup, 2 itemsEli Lillyorforglipron